Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia

被引:1
作者
Mahar, Kelly M. [1 ]
Yang, Shuying [2 ]
Mesic, Emir [3 ]
Post, Teun M. [3 ]
Goulooze, Sebastiaan C. [3 ]
机构
[1] GSK, Collegeville, PA 19426 USA
[2] GSK, London, England
[3] LAP & P Consultants, Leiden Experts Adv Pharmacokinet & Pharmacodynam L, Leiden, Netherlands
关键词
PROLYL HYDROXYLASE INHIBITOR; MODEL; PSN;
D O I
10.1007/s40262-024-01417-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveDaprodustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the USA for treatment of anemia owing to chronic kidney disease (CKD) in dialysis-dependent adults and in Japan for treatment of CKD in dialysis- and non-dialysis dependent adults. This analysis characterized the population pharmacokinetics (PopPK) of daprodustat in adults with CKD and evaluated the influence of intrinsic and extrinsic factors.MethodsThis PopPK analysis included data from one phase 2B and four phase 3 studies comprising 707 CKD subjects dose titrated to prespecified target hemoglobin levels with daprodustat doses ranging from 1 to 24 mg once daily and 2 to 48 mg given three times a week (TIW). Model development leveraged a previous phase 1/2 PopPK model. Stepwise covariate analysis included 20 extrinsic and intrinsic factors. Model evaluation used standard goodness-of-fit and visual predictive checks.ResultsDaprodustat PopPK was adequately characterized using a three-compartment distribution model with first-order elimination. The absorption phase was described using five transit compartments. Oral clearance and volume of distribution was 24.6 L/h and 26.9 L, respectively. Body weight dependence (with fixed allometric coefficients) of clearance and volume terms was a statistically significant covariate. Concomitant use of clopidogrel (moderate CYP2C8 inhibitor) decreased oral clearance, resulting in higher area under the plasma concentration-time curve (AUC) ratio of 1.59 (90% CI: 1.39-1.82), subjects' dialysis status (non-dialysis versus dialysis) had an effect on absorption, with Cmax ratio of 1.19 (90% CI: 1.09-1.30). None of the other investigated intrinsic or extrinsic covariates, including concomitant administration with phosphate binders, oral iron and acid reducing agents resulted in a significant change in daprodustat systemic exposure.ConclusionThe PopPK of daprodustat in the CKD population with anemia was adequately characterized. Allometrically-scaled body weight on clearance and volume, dialysis status on absorption and clopidogrel on clearance were statistically significant covariates.
引用
收藏
页码:1327 / 1341
页数:15
相关论文
共 50 条
  • [21] Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis
    Fadlalmola, Hammad Ali
    Al-Sayaghi, Khaled Mohammed
    Al-Hebshi, Abdulqader Abdlah
    Alhujaily, Muhanad
    Alyamani, Arwa Omar
    Alem, Alaa Abdulrhman
    Syrafi, Mona Hamza
    Alem, Sarah
    Farhat, Afrah Hassan
    Mohamed, Fathi Abdelrazig
    Abdalrahman, Hager Hassan
    Abdelmalik, Mohammed Abdelkrim
    Abdalrhman, Neimat Mahmoud
    Eltayeb, Alamin Mustafa
    PAN AFRICAN MEDICAL JOURNAL, 2024, 47
  • [22] Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease
    Hasegawa, Sho
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2018, 27 (05) : 331 - 338
  • [23] Predicting Hospitalizations for Patients With Chronic Kidney Disease
    Karpinski, Steph
    Sibbel, Scott
    Gray, Kathryn
    Walker, Adam G.
    Luo, Jiacong
    Colson, Carey
    Stebbins, Juliana
    Brunelli, Steven M.
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (09) : E262 - E266
  • [24] Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
    Ku, Elaine
    Del Vecchio, Lucia
    Eckardt, Kai-Uwe
    Haase, Volker H.
    Johansen, Kirsten L.
    Nangaku, Masaomi
    Tangri, Navdeep
    Waikar, Sushrut S.
    Wiecek, Andrzej
    Cheung, Michael
    Jadoul, Michel
    Winkelmayer, Wolfgang C.
    Wheeler, David C.
    KIDNEY INTERNATIONAL, 2023, 104 (04) : 655 - 680
  • [25] Dosage Optimization of Digoxin in Older Patients with Heart Failure and Chronic Kidney Disease: A Population Pharmacokinetic Analysis
    Lin, Zhong-Qiu
    Guo, Ling
    Zhang, Li-Min
    Lu, Jie-Jiu
    Jiang, Xia
    DRUGS & AGING, 2023, 40 (06) : 539 - 549
  • [26] Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
    Paule, Ines
    Sassi, Hind
    Habibi, Anoosha
    Pham, Kim P. D.
    Bachir, Dora
    Galacteros, Frederic
    Girard, Pascal
    Hulin, Anne
    Tod, Michel
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [27] Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation
    Zwart, Tom C.
    Bezstarosti, Suzanne
    Achini, Federica R.
    Reinders, Marlies E. J.
    Schilham, Marco W.
    Heidt, Sebastiaan
    Guchelaar, Henk-Jan
    de Fijter, Johan W.
    Moes, Dirk Jan A. R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (04) : 1471 - 1485
  • [28] Insulin resistance in nondiabetic chronic kidney disease patients
    Nallamothu, Praveen
    Nimmanapalli, Harini Devi
    Sachan, Alok
    Rao, Srinivasa
    Vishnubotla, Sivakumar
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2021, 32 (05) : 1300 - 1309
  • [29] Projection of the health and economic impacts of Chronic kidney disease in the Chilean population
    Walbaum, Magdalena
    Scholes, Shaun
    Rojas, Ruben
    Mindell, Jennifer S.
    Pizzo, Elena
    PLOS ONE, 2021, 16 (09):
  • [30] Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant
    Eduardo Resendiz-Galvan, Juan
    Edith Medellin-Garibay, Susanna
    del Carmen Milan-Segovia, Rosa
    del Carmen Nino-Moreno, Perla
    Isordia-Segovia, Javier
    Romano-Moreno, Silvia
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (03) : 303 - 311